SlideShare ist ein Scribd-Unternehmen logo
1 von 19
Downloaden Sie, um offline zu lesen
Genimen Pharmacon Pvt. Ltd
Address: 11/5/1A, Ram Krishna Das Lane,
Kolkata-700009,
West Bengal,
India
Webpage: www.genimenpharmacon.com
Email: genimen.pharmacon@gmail.com
Mobile: 8334080000/8582806092/9836592580/+44 7741353824
About Us
Genimen Pharmacon stands for bioactive compounds from fruits as the word.
Genimen means Fruit / the Product whereas Pharmacon means biologically active
substance.
Genimen Pharmacon was formed by young Entrepreneurs who share a common
belief that as much as it is important in healing people it is equally important in
preventing the disease. The most significant idea which gave birth to Genimen
was to work with products which can have significant effects on human health.
Genimen Pharmacon focuses on cardiovascular disease (CVD) as it is the number
one cause of deaths throughout the world
Analytical Purview
Hypertension has been identified with the most significant
CVD risk factors for causing diseases like Cardiac
Infarction, Stroke and Renal Failure. Hence, hypertension
has been coined the term ‘The Silent Killer’.
Fig1 the 10 Leading causes of death in the world (2012) Fig 2 the projected mortality trend
Global death rates taken from WHO (World Health Organization)
Cardiovascular Risk Factors
12 factors that increase the risk of Heart Disease and Heart Attack:
 High Blood Pressure
 High blood Cholesterol
 Platelet hyperactivity
 Obesity and Overweight
 Diabetes Mellitus
 Life style factors
 Physical Inactivity
 Tobacco Smoke
 Stress
 Alcohol
 Diet and Nutrition
 Age
Key Facts and Collaborations…..
Genimen Pharmacon has collaborated with Inven2, Oslo Norway
(www.inven2.com), owned by the University of Oslo and Oslo
University Hospital, Norway's largest and leading university and
hospital representing pioneering research. Genimen Pharmacon
has been given the license to manufacture and develop the
internationally patented cardio protective factors present in
specially isolated Kiwi Fruit Extract (KFE) for its commercialization
in India.
Genimen Pharmacon is the only company in India that holds KFE
license.
Professor Asim Duttaroy (www.asimduttaroy.com) at the
University of Oslo isolated a specific fraction of the kiwifruit.
The extract is composed of a multitude of small water-
soluble molecules that contribute to the desired bioactivity.
The bioactivities include reducing angiotensin converting
enzyme and platelet aggregation response, those are
responsible for lowering blood pressure and improving
circulation. These activities have been demonstrated both in
vitro and ex vivo.
In addition, the previous randomized and controlled clinical
trials, whole kiwifruit has been shown to give significant
effects on blood pressure and platelet aggregation. The trials
indicate that consumption of whole kiwifruit can lead to a
reduction in blood pressure between 5 and 10 mmHg as
shown here.
Professor Duttaroy has also tested the extract in several in
vitro and ex vivo assays and documented inhibitory effects on
blood platelet aggregation and the activity of enzyme,
Angiotensin Converting enzyme (ACE), essential to the
regulation of blood pressure.(Refs)
KFE will be marketed as Kiwidrin in India by us
India’s loss in terms of losing potentially productive years due to death from cardiovascular
disease in people aged between 35 – 64 years is one of the highest in the world. By 2030 loss
is expected to rise to 17.9 million years which is 940 percent more than the loss estimated in
USA.
Number of people with hypertension is expected to see a quantum leap from an estimated
118.2 million in 2000 to 213.5 million in 2025.
The projected forgone National Income for India due to Heart disease, Stroke and Diabetes
during the period 2005 to 2015 is estimated to be more than USD 200 Billion.
These facts clearly reveal that CVD is the most lethal disease in terms of morbidity, mortality
and productivity and social cost in India.
Wendell Berry said “People are fed by the food Industry which pays no attention to
health, and treated by the health Industry which pays no attention to food”. Genimen
Pharmacon acknowledges the fact and since "Prevention is better than cure” ended up
signing the KFE License with the noble intension of preventing people from developing CVD.
INDIA – A Perspective (Source: PWC)
Dr. Prof Asim Duttaroy’s previous product “Fruitflow®”, an EFSA (European Food Safety
Authority) approved which is a Tomato extract was awarded as one of the most innovative
product of the year in 2012. Kiwidrin (KFE) also shows similar mechanism of action in
lowering blood Pressure and Platelet aggregation response. Work is now being carried out for
EFSA approval of KFE by the Norwegian company, IDIA. AS.
Hence Kiwidrin is not only a revolutionary but an evolutionary one and is sure to enjoy
success in Indian markets.
Advantages of Kiwidrin:
 Reduces Platelet aggregation
 Reduces Blood Pressure level
 Reduces Triglycerides level
 No resistance (Compared to Aspirin which has around 30 % resistance)
 No drug interactions expected
 No allergy (as all the known allergens are removed while the extract is being produced)
LAST BUT NOT THE LEAST…
 No side effects (Compared to Aspirin which affects GI tract)
A Prelude
USP of Kiwidrin
 Presence of potent antiplatelet and anti
hypertensive factors in Kiwidrin
 These factors are water soluble, heat stable and
molecular size less than 1000 Da
 A unique value creation opportunity in the
cardiovascular health market
 As an extractor mixed with juice or margarine it
becomes bioavailable in humans within 2 hours
of consumption
Kiwi Sugar-free Powder
Kiwi Syrup Extract
The Customers and the Food & Beverage Industry
The nutritional ingredients market is driven by:
• The increasing awareness of the intimate connection between food and health
• The growing scientific support for nutritional health claims.
• The urge to prevent disease and curb the increasing costs in the healthcare sector
The nutritional ingredients market is currently estimated at 24 billion USD with a steady high single-digit
growth rate. Due to a significant shift in the preferences of consumers, new functional ingredients are
typically derived from natural sources like vegetables, fruits, or other plants
The marketplace is heavily influenced by the changes in the regulatory framework with more rigid
demands on documentation of efficacy. As to be expected in an emerging market in an early phase, the
competitors are few in India.
The Business Model and Market Access
Genimen will market Kiwidrin and offer this high-quality ingredient with
its documented effects directly to end-producers in the food and
beverage industry, and also as food supplement. The production of the
ingredient is a simple extraction/production process expected to lead to
acceptable production costs and cost in use. Future manufacturing for
commercial purposes will be outsourced from IDIA AS, a Norwegian
company, which holds worldwide license right of KFE except India.
The strength of the ingredient will be established through a well-planned
clinical development process and a forward integration marketing
strategy. The beneficial effects of the ingredient on human health will be
documented, leading to an application for an FSSAI approval of cardio-
protective health claims. The ingredient will be branded and protected
under a proprietary trademark.
The competitive edge of the extract is based on its efficacy and wide
applicability leading to opportunities for positioning as a functional and
natural ingredient. It is expected to show a clinically relevant effect on
blood pressure and to be well suited for a wide range of food and
beverages
Executive Team Introduction
 Aniruddha Som is one of the pillars of Genimen Pharmacon. He has started his career being
an entrepreneur in the field of Information Technology. Genimen Pharmacon has been very
fortunate in tapping the expertise of Aniruddha through his entrepreneurship skills and
abilities. He is very specific in his requirements and knows exactly what the company
requires at a specific point. Aniruddha holds a Master’s degree in Computer Applications.
Aniruddha is a board member of Genimen Pharmacon in the capacity of Digital Marketing and
IT compliance. Genimen Pharmacon wouldn’t be possible without his involvements. He makes
a brilliant team player.
 Dr. Mayukh Sardar is an experienced doctor by profession. He has an expert insight in the
kind of products Genimen Pharmacon works with. Mayukh is holding a post-doctoral degree
from the Barts and The London School of Medicine and Dentistry. Mayukh’s ardent passion has
let him become an entrepreneur with Genimen Pharmacon. Mayukh is very focused with his
work. He is a very enthusiastic person and a very good listener. Mayukh is very rational with
his approach. Mayukh’s experience in his field of work and the kind of person he is has helped
Genimen Pharmacon to make its footprint in the Biotech Industry.
Executive Team Introduction
 Prithwiraj Bhattacharyya is having more than 8 years of combined experience in the field of
Pharmaceuticals, Airlines and most recently in the consulting space with IBM. He is a Master’s
degree holder in the field of Management and is having a Bachelor’s degree in Genetics from
Bangalore University. He has served across a variety of clients and the experience gained within
has been a pioneering force in the induction of Genimen Pharmacon. He is serving the board of
Genimen Pharmacon as a marketing and communications. Prithwiraj is most passionate about his
work and is driven by core ethical values.
 Rajesh Banerjee is another key member in the company. Rajesh is currently based out of UK.
Rajesh is having good acumen in business and GP would be happy to tap into his resources. Rajesh
would be primarily looking into market expansion.
 Dr. Asim Duttaroy, who is the inventor of the product and based in Oslo is in the scientific advisory
board of Genimen. He is a globally recognized expert in the field of nutrition research. Professor
Duttaroy is currently Group Leader of Chronic Disease at the University of Oslo’s Faculty of
Medicine, and he is the editor in chief of the international peer reviewed journal Food & Nutrition
Research. His scientific work has been published in over 175 original contributions, reviews, book,
and editorials. He owns several international patents. His discoveries of anti-thrombotic factors in
tomatoes and kiwifruits are patented internationally and 2 companies, Provexis Limited
(www.provexis.com) in UK, and IDIA AS (www.idia.no) in Norway are established to commercialize
these discoveries.
Growth Rate
The Nutraceutical market in India is estimated to grow to $2731 Million in 2016 at
a CAGR (compound annual growth rate) of 13% and the revenues expected to reach
approximately USD 4.2 billion in 2017.
Investments
Genimen is currently seeking funding for the implementation
of the development plan leading to an FSSAI approval of
health claims and full market access. The development is
expected to continue to be supported by public funding.
Genimen is extensively trying to raise the fund that provides
funding for its corporate activities through 2015.
Achievements and Targets
 Genimen Pharmacon has won over the KFE license from Inven2 outperforming other competitors
 We are on negotiating phase with IDIA AS, a Norwegian company which is holding the KFE License on a
global platform (India excluded) for manufacturing and supplying of KFE for some of IDIA’s territory
 Genimen Pharmacon is trying to collaborate with IDIA on mutual sharing of clinical trial data, allowing
us to get the first hand data ensuring data quality
 Prof Asim Duttaroy is the member of the scientific advisory board of Genimen Pharmacon
 We are in touch with FSSAI (food safety and standards authority of India) pertaining to the regulatory
approval of Kiwidrin for its commercialization in India
Genimen Pharmacon has been able to achieve the above milestone over a span of few months only and
working relentlessly towards the achievement of its targets.
Going forward we need to forth set our strategic plan in taking the KFE to the end consumers. We
welcome rational investors in aiding us financially to take things ahead from here.
FAQ’S
1) What is the issue / pain point that your product / solution
addresses
• Explain why your customers need your solution …...
Genimen Pharmacon focuses on cardiovascular disease (CVD) as
it is the number one cause of death throughout the world
based on report from World Health Organization
• Mention what they are currently doing and how your
product/service is a better solution ….
They are either on low dose Aspirin or other antihypertensive
drug which are synthetically made and has got side effects.
Better Solution because our product will be used for lowering
down the risk of CVD and is a natural extract which has no side
effect.
Moreover Aspirin has been rejected by USFDA for its use as
primary prevention of CVD because there are serious risks
associated with the use of aspirin, including increased risk of
bleeding in the stomach and brain, in situations where the
benefit of aspirin for primary prevention has not been
established.
FAQ’S…
2) Business model
• This is about how you will make money from this business opportunity.
1. According to WHO data CVD is the number one causative factor for death all over the world and India which holds 1/6th of
world’s population is of no exception
2. We are the sole licensee in India
3. Plan is to go for contract manufacturing and distribution with Grade 1 Company having Nutraceutical manufacturing license.
Preferably on a royalty basis or profit sharing percentage.
4. The revenue generation will be huge naturally
3) What is the size of the market opportunity?
As per the census of 2010, the percentage age group between 15 to 59 age is 61.6 %
(http://www.censusindia.gov.in/vital_statistics/srs/Chap_2_-_2010.pdf)
We are assuming the target age group to be of 25 to 60 years. Based on conventional approach 77.77 % of population should be
between 25 to 60 which will be our target group. Now 61.6 percent of Indian population comes around 74 crores approximately
whose 77.77 percent roughly becomes 57 crores. Even if we consider 10 percent of the population (5.7 crores approx) buys our
product which may have a profit of Re 1 per capsule, still we end up with a profit of around (5.7 * 30) 171 crores on monthly
basis.
All this is at the start up level.
Products in the pipe line
Genimen Pharmacon is also doing research and development for the following
diseases which are growing at an alarming rate globally
 Diabetes mellitus
 Foetal health and development
 Memory Disorders
 Preeclampsia and pregnancy disorders
Thank You

Weitere ähnliche Inhalte

Was ist angesagt?

FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015Sabarinath Suryaprakash
 
Branded Generics Vs Generics - A Recipe for Confusion by Dr. Sumit Ghosal
Branded Generics Vs Generics - A Recipe for Confusion by Dr. Sumit GhosalBranded Generics Vs Generics - A Recipe for Confusion by Dr. Sumit Ghosal
Branded Generics Vs Generics - A Recipe for Confusion by Dr. Sumit GhosalAnup Soans
 
IMA Letter on Prescribing Generics
IMA Letter on Prescribing GenericsIMA Letter on Prescribing Generics
IMA Letter on Prescribing GenericsAnup Soans
 
Biocon business ethics
Biocon business ethicsBiocon business ethics
Biocon business ethicsakashbalram
 
Cipla presentation
Cipla presentationCipla presentation
Cipla presentationMdNadeem25
 
Product Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sProduct Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sAnimesh Gupta
 
Biocon AGM 2012 Presentation July 26, 2012
Biocon AGM 2012 Presentation July 26, 2012Biocon AGM 2012 Presentation July 26, 2012
Biocon AGM 2012 Presentation July 26, 2012Biocon
 
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. Shantanu Kumar Singh
 
Research Report on Cipla Limited
Research Report on Cipla Limited Research Report on Cipla Limited
Research Report on Cipla Limited Aditya Arora
 
Ranbaxy and mankind pharmaceutical
Ranbaxy  and mankind pharmaceuticalRanbaxy  and mankind pharmaceutical
Ranbaxy and mankind pharmaceuticalabhishek_jaiswal
 
Best innovative pharmaceuticals firm, 2020..
Best innovative pharmaceuticals firm, 2020..Best innovative pharmaceuticals firm, 2020..
Best innovative pharmaceuticals firm, 2020..SophiaSmeeth
 
Pharmaceuticals, Biotechnology and Life Sciences - Australian Stock Market Re...
Pharmaceuticals, Biotechnology and Life Sciences - Australian Stock Market Re...Pharmaceuticals, Biotechnology and Life Sciences - Australian Stock Market Re...
Pharmaceuticals, Biotechnology and Life Sciences - Australian Stock Market Re...Share Trading
 

Was ist angesagt? (20)

FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
 
Cipla Presentation
Cipla PresentationCipla Presentation
Cipla Presentation
 
Branded Generics Vs Generics - A Recipe for Confusion by Dr. Sumit Ghosal
Branded Generics Vs Generics - A Recipe for Confusion by Dr. Sumit GhosalBranded Generics Vs Generics - A Recipe for Confusion by Dr. Sumit Ghosal
Branded Generics Vs Generics - A Recipe for Confusion by Dr. Sumit Ghosal
 
IMA Letter on Prescribing Generics
IMA Letter on Prescribing GenericsIMA Letter on Prescribing Generics
IMA Letter on Prescribing Generics
 
Biocon business ethics
Biocon business ethicsBiocon business ethics
Biocon business ethics
 
OPPI in Media
OPPI in MediaOPPI in Media
OPPI in Media
 
Cipla presentation
Cipla presentationCipla presentation
Cipla presentation
 
Mankind pharma ppt
Mankind pharma pptMankind pharma ppt
Mankind pharma ppt
 
Vision 2022 Roadmap study for Indian Ayurveda Industry
Vision 2022 Roadmap study for Indian Ayurveda IndustryVision 2022 Roadmap study for Indian Ayurveda Industry
Vision 2022 Roadmap study for Indian Ayurveda Industry
 
Product Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sProduct Mix of Dr. Reddy's
Product Mix of Dr. Reddy's
 
Biocon AGM 2012 Presentation July 26, 2012
Biocon AGM 2012 Presentation July 26, 2012Biocon AGM 2012 Presentation July 26, 2012
Biocon AGM 2012 Presentation July 26, 2012
 
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
 
Research Report on Cipla Limited
Research Report on Cipla Limited Research Report on Cipla Limited
Research Report on Cipla Limited
 
Biocon Company Profile
Biocon Company ProfileBiocon Company Profile
Biocon Company Profile
 
Divi's lab Presentation
Divi's lab PresentationDivi's lab Presentation
Divi's lab Presentation
 
Ranbaxy and mankind pharmaceutical
Ranbaxy  and mankind pharmaceuticalRanbaxy  and mankind pharmaceutical
Ranbaxy and mankind pharmaceutical
 
Best innovative pharmaceuticals firm, 2020..
Best innovative pharmaceuticals firm, 2020..Best innovative pharmaceuticals firm, 2020..
Best innovative pharmaceuticals firm, 2020..
 
Herbal Prospects
Herbal ProspectsHerbal Prospects
Herbal Prospects
 
Pedia sure
Pedia surePedia sure
Pedia sure
 
Pharmaceuticals, Biotechnology and Life Sciences - Australian Stock Market Re...
Pharmaceuticals, Biotechnology and Life Sciences - Australian Stock Market Re...Pharmaceuticals, Biotechnology and Life Sciences - Australian Stock Market Re...
Pharmaceuticals, Biotechnology and Life Sciences - Australian Stock Market Re...
 

Andere mochten auch

The Bankers are Turning Nasty v3
The Bankers are Turning Nasty v3The Bankers are Turning Nasty v3
The Bankers are Turning Nasty v3Simon Michaux
 
Project Optimisation
Project OptimisationProject Optimisation
Project OptimisationSimon Michaux
 
SamuelRios_Project Management
SamuelRios_Project ManagementSamuelRios_Project Management
SamuelRios_Project ManagementSam Rios
 
Coffee bags (kaffee verpackung )
Coffee bags (kaffee verpackung )Coffee bags (kaffee verpackung )
Coffee bags (kaffee verpackung )Thomas Smith
 
Geomet for process design 8 8 2012 kv
Geomet for process design 8 8 2012 kvGeomet for process design 8 8 2012 kv
Geomet for process design 8 8 2012 kvSimon Michaux
 
Toan (mau moi)
Toan (mau moi)Toan (mau moi)
Toan (mau moi)Đối Cá
 

Andere mochten auch (7)

The Bankers are Turning Nasty v3
The Bankers are Turning Nasty v3The Bankers are Turning Nasty v3
The Bankers are Turning Nasty v3
 
Shahzad
ShahzadShahzad
Shahzad
 
Project Optimisation
Project OptimisationProject Optimisation
Project Optimisation
 
SamuelRios_Project Management
SamuelRios_Project ManagementSamuelRios_Project Management
SamuelRios_Project Management
 
Coffee bags (kaffee verpackung )
Coffee bags (kaffee verpackung )Coffee bags (kaffee verpackung )
Coffee bags (kaffee verpackung )
 
Geomet for process design 8 8 2012 kv
Geomet for process design 8 8 2012 kvGeomet for process design 8 8 2012 kv
Geomet for process design 8 8 2012 kv
 
Toan (mau moi)
Toan (mau moi)Toan (mau moi)
Toan (mau moi)
 

Ähnlich wie Genimen pharmacon pvt ltd

Summer Internship Report
Summer Internship ReportSummer Internship Report
Summer Internship ReportPramod Patidar
 
A study on sales and promotion startegies towards Excellent Biotechnologies
A study on sales and promotion startegies towards Excellent Biotechnologies A study on sales and promotion startegies towards Excellent Biotechnologies
A study on sales and promotion startegies towards Excellent Biotechnologies Muneer Mohammed
 
Research Project on Factors affecting Employees Satisfaction
  Research Project on Factors affecting Employees Satisfaction   Research Project on Factors affecting Employees Satisfaction
Research Project on Factors affecting Employees Satisfaction Kushagra Purohit
 
Development of Biopharmaceuticals Industry in India
Development of Biopharmaceuticals Industry in IndiaDevelopment of Biopharmaceuticals Industry in India
Development of Biopharmaceuticals Industry in IndiaBhaswat Chakraborty
 
The pharma outlook 2015
The pharma outlook 2015 The pharma outlook 2015
The pharma outlook 2015 Namdeo Shinde
 
Company profile Firstmed Pharma 2013
Company profile Firstmed Pharma 2013Company profile Firstmed Pharma 2013
Company profile Firstmed Pharma 2013Cesar Cuneo
 
Vedic Lifesciences - Nutraceutical CRO
Vedic Lifesciences - Nutraceutical CROVedic Lifesciences - Nutraceutical CRO
Vedic Lifesciences - Nutraceutical CROJayesh Chaudhary
 
Top 10 Cardiac Diabetic Companies in India (1).pdf
Top 10 Cardiac Diabetic Companies in India (1).pdfTop 10 Cardiac Diabetic Companies in India (1).pdf
Top 10 Cardiac Diabetic Companies in India (1).pdfLifecareCardioDiabet
 
India's leading pharmaceutical company 2021
India's leading pharmaceutical company   2021India's leading pharmaceutical company   2021
India's leading pharmaceutical company 2021Merry D'souza
 
10 Best Companies in Nutraceutical Market 2022.pdf
10 Best Companies in Nutraceutical Market 2022.pdf10 Best Companies in Nutraceutical Market 2022.pdf
10 Best Companies in Nutraceutical Market 2022.pdfinsightscare
 
The 10 most admired pharma companies in 2018
The 10 most admired pharma companies in 2018 The 10 most admired pharma companies in 2018
The 10 most admired pharma companies in 2018 Merry D'souza
 

Ähnlich wie Genimen pharmacon pvt ltd (20)

CDXC Corporate presentation
CDXC Corporate presentationCDXC Corporate presentation
CDXC Corporate presentation
 
Summer Internship Report
Summer Internship ReportSummer Internship Report
Summer Internship Report
 
11 cdxc
11 cdxc11 cdxc
11 cdxc
 
The 10 most eminent leaders in pharmaceutical industry, 2021 compressed
The 10 most eminent leaders in pharmaceutical industry, 2021 compressedThe 10 most eminent leaders in pharmaceutical industry, 2021 compressed
The 10 most eminent leaders in pharmaceutical industry, 2021 compressed
 
A study on sales and promotion startegies towards Excellent Biotechnologies
A study on sales and promotion startegies towards Excellent Biotechnologies A study on sales and promotion startegies towards Excellent Biotechnologies
A study on sales and promotion startegies towards Excellent Biotechnologies
 
Research Project on Factors affecting Employees Satisfaction
  Research Project on Factors affecting Employees Satisfaction   Research Project on Factors affecting Employees Satisfaction
Research Project on Factors affecting Employees Satisfaction
 
internship report
internship reportinternship report
internship report
 
Development of Biopharmaceuticals Industry in India
Development of Biopharmaceuticals Industry in IndiaDevelopment of Biopharmaceuticals Industry in India
Development of Biopharmaceuticals Industry in India
 
The pharma outlook 2015
The pharma outlook 2015 The pharma outlook 2015
The pharma outlook 2015
 
Pfizer Inc
Pfizer IncPfizer Inc
Pfizer Inc
 
Pfizer Inc
Pfizer IncPfizer Inc
Pfizer Inc
 
Company profile Firstmed Pharma 2013
Company profile Firstmed Pharma 2013Company profile Firstmed Pharma 2013
Company profile Firstmed Pharma 2013
 
Vedic Lifesciences - Nutraceutical CRO
Vedic Lifesciences - Nutraceutical CROVedic Lifesciences - Nutraceutical CRO
Vedic Lifesciences - Nutraceutical CRO
 
Biological E Limited
Biological E LimitedBiological E Limited
Biological E Limited
 
Top 10 Cardiac Diabetic Companies in India (1).pdf
Top 10 Cardiac Diabetic Companies in India (1).pdfTop 10 Cardiac Diabetic Companies in India (1).pdf
Top 10 Cardiac Diabetic Companies in India (1).pdf
 
Pharmacy report
Pharmacy reportPharmacy report
Pharmacy report
 
Amgen pharma
Amgen pharmaAmgen pharma
Amgen pharma
 
India's leading pharmaceutical company 2021
India's leading pharmaceutical company   2021India's leading pharmaceutical company   2021
India's leading pharmaceutical company 2021
 
10 Best Companies in Nutraceutical Market 2022.pdf
10 Best Companies in Nutraceutical Market 2022.pdf10 Best Companies in Nutraceutical Market 2022.pdf
10 Best Companies in Nutraceutical Market 2022.pdf
 
The 10 most admired pharma companies in 2018
The 10 most admired pharma companies in 2018 The 10 most admired pharma companies in 2018
The 10 most admired pharma companies in 2018
 

Kürzlich hochgeladen

High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essAbhishekKumar524514
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentationmarwaahmad357
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 

Kürzlich hochgeladen (20)

High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well ess
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentation
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 

Genimen pharmacon pvt ltd

  • 1. Genimen Pharmacon Pvt. Ltd Address: 11/5/1A, Ram Krishna Das Lane, Kolkata-700009, West Bengal, India Webpage: www.genimenpharmacon.com Email: genimen.pharmacon@gmail.com Mobile: 8334080000/8582806092/9836592580/+44 7741353824
  • 2. About Us Genimen Pharmacon stands for bioactive compounds from fruits as the word. Genimen means Fruit / the Product whereas Pharmacon means biologically active substance. Genimen Pharmacon was formed by young Entrepreneurs who share a common belief that as much as it is important in healing people it is equally important in preventing the disease. The most significant idea which gave birth to Genimen was to work with products which can have significant effects on human health. Genimen Pharmacon focuses on cardiovascular disease (CVD) as it is the number one cause of deaths throughout the world
  • 3. Analytical Purview Hypertension has been identified with the most significant CVD risk factors for causing diseases like Cardiac Infarction, Stroke and Renal Failure. Hence, hypertension has been coined the term ‘The Silent Killer’. Fig1 the 10 Leading causes of death in the world (2012) Fig 2 the projected mortality trend Global death rates taken from WHO (World Health Organization)
  • 4. Cardiovascular Risk Factors 12 factors that increase the risk of Heart Disease and Heart Attack:  High Blood Pressure  High blood Cholesterol  Platelet hyperactivity  Obesity and Overweight  Diabetes Mellitus  Life style factors  Physical Inactivity  Tobacco Smoke  Stress  Alcohol  Diet and Nutrition  Age
  • 5. Key Facts and Collaborations….. Genimen Pharmacon has collaborated with Inven2, Oslo Norway (www.inven2.com), owned by the University of Oslo and Oslo University Hospital, Norway's largest and leading university and hospital representing pioneering research. Genimen Pharmacon has been given the license to manufacture and develop the internationally patented cardio protective factors present in specially isolated Kiwi Fruit Extract (KFE) for its commercialization in India. Genimen Pharmacon is the only company in India that holds KFE license.
  • 6. Professor Asim Duttaroy (www.asimduttaroy.com) at the University of Oslo isolated a specific fraction of the kiwifruit. The extract is composed of a multitude of small water- soluble molecules that contribute to the desired bioactivity. The bioactivities include reducing angiotensin converting enzyme and platelet aggregation response, those are responsible for lowering blood pressure and improving circulation. These activities have been demonstrated both in vitro and ex vivo. In addition, the previous randomized and controlled clinical trials, whole kiwifruit has been shown to give significant effects on blood pressure and platelet aggregation. The trials indicate that consumption of whole kiwifruit can lead to a reduction in blood pressure between 5 and 10 mmHg as shown here. Professor Duttaroy has also tested the extract in several in vitro and ex vivo assays and documented inhibitory effects on blood platelet aggregation and the activity of enzyme, Angiotensin Converting enzyme (ACE), essential to the regulation of blood pressure.(Refs) KFE will be marketed as Kiwidrin in India by us
  • 7. India’s loss in terms of losing potentially productive years due to death from cardiovascular disease in people aged between 35 – 64 years is one of the highest in the world. By 2030 loss is expected to rise to 17.9 million years which is 940 percent more than the loss estimated in USA. Number of people with hypertension is expected to see a quantum leap from an estimated 118.2 million in 2000 to 213.5 million in 2025. The projected forgone National Income for India due to Heart disease, Stroke and Diabetes during the period 2005 to 2015 is estimated to be more than USD 200 Billion. These facts clearly reveal that CVD is the most lethal disease in terms of morbidity, mortality and productivity and social cost in India. Wendell Berry said “People are fed by the food Industry which pays no attention to health, and treated by the health Industry which pays no attention to food”. Genimen Pharmacon acknowledges the fact and since "Prevention is better than cure” ended up signing the KFE License with the noble intension of preventing people from developing CVD. INDIA – A Perspective (Source: PWC)
  • 8. Dr. Prof Asim Duttaroy’s previous product “Fruitflow®”, an EFSA (European Food Safety Authority) approved which is a Tomato extract was awarded as one of the most innovative product of the year in 2012. Kiwidrin (KFE) also shows similar mechanism of action in lowering blood Pressure and Platelet aggregation response. Work is now being carried out for EFSA approval of KFE by the Norwegian company, IDIA. AS. Hence Kiwidrin is not only a revolutionary but an evolutionary one and is sure to enjoy success in Indian markets. Advantages of Kiwidrin:  Reduces Platelet aggregation  Reduces Blood Pressure level  Reduces Triglycerides level  No resistance (Compared to Aspirin which has around 30 % resistance)  No drug interactions expected  No allergy (as all the known allergens are removed while the extract is being produced) LAST BUT NOT THE LEAST…  No side effects (Compared to Aspirin which affects GI tract) A Prelude
  • 9. USP of Kiwidrin  Presence of potent antiplatelet and anti hypertensive factors in Kiwidrin  These factors are water soluble, heat stable and molecular size less than 1000 Da  A unique value creation opportunity in the cardiovascular health market  As an extractor mixed with juice or margarine it becomes bioavailable in humans within 2 hours of consumption Kiwi Sugar-free Powder Kiwi Syrup Extract
  • 10. The Customers and the Food & Beverage Industry The nutritional ingredients market is driven by: • The increasing awareness of the intimate connection between food and health • The growing scientific support for nutritional health claims. • The urge to prevent disease and curb the increasing costs in the healthcare sector The nutritional ingredients market is currently estimated at 24 billion USD with a steady high single-digit growth rate. Due to a significant shift in the preferences of consumers, new functional ingredients are typically derived from natural sources like vegetables, fruits, or other plants The marketplace is heavily influenced by the changes in the regulatory framework with more rigid demands on documentation of efficacy. As to be expected in an emerging market in an early phase, the competitors are few in India.
  • 11. The Business Model and Market Access Genimen will market Kiwidrin and offer this high-quality ingredient with its documented effects directly to end-producers in the food and beverage industry, and also as food supplement. The production of the ingredient is a simple extraction/production process expected to lead to acceptable production costs and cost in use. Future manufacturing for commercial purposes will be outsourced from IDIA AS, a Norwegian company, which holds worldwide license right of KFE except India. The strength of the ingredient will be established through a well-planned clinical development process and a forward integration marketing strategy. The beneficial effects of the ingredient on human health will be documented, leading to an application for an FSSAI approval of cardio- protective health claims. The ingredient will be branded and protected under a proprietary trademark. The competitive edge of the extract is based on its efficacy and wide applicability leading to opportunities for positioning as a functional and natural ingredient. It is expected to show a clinically relevant effect on blood pressure and to be well suited for a wide range of food and beverages
  • 12. Executive Team Introduction  Aniruddha Som is one of the pillars of Genimen Pharmacon. He has started his career being an entrepreneur in the field of Information Technology. Genimen Pharmacon has been very fortunate in tapping the expertise of Aniruddha through his entrepreneurship skills and abilities. He is very specific in his requirements and knows exactly what the company requires at a specific point. Aniruddha holds a Master’s degree in Computer Applications. Aniruddha is a board member of Genimen Pharmacon in the capacity of Digital Marketing and IT compliance. Genimen Pharmacon wouldn’t be possible without his involvements. He makes a brilliant team player.  Dr. Mayukh Sardar is an experienced doctor by profession. He has an expert insight in the kind of products Genimen Pharmacon works with. Mayukh is holding a post-doctoral degree from the Barts and The London School of Medicine and Dentistry. Mayukh’s ardent passion has let him become an entrepreneur with Genimen Pharmacon. Mayukh is very focused with his work. He is a very enthusiastic person and a very good listener. Mayukh is very rational with his approach. Mayukh’s experience in his field of work and the kind of person he is has helped Genimen Pharmacon to make its footprint in the Biotech Industry.
  • 13. Executive Team Introduction  Prithwiraj Bhattacharyya is having more than 8 years of combined experience in the field of Pharmaceuticals, Airlines and most recently in the consulting space with IBM. He is a Master’s degree holder in the field of Management and is having a Bachelor’s degree in Genetics from Bangalore University. He has served across a variety of clients and the experience gained within has been a pioneering force in the induction of Genimen Pharmacon. He is serving the board of Genimen Pharmacon as a marketing and communications. Prithwiraj is most passionate about his work and is driven by core ethical values.  Rajesh Banerjee is another key member in the company. Rajesh is currently based out of UK. Rajesh is having good acumen in business and GP would be happy to tap into his resources. Rajesh would be primarily looking into market expansion.  Dr. Asim Duttaroy, who is the inventor of the product and based in Oslo is in the scientific advisory board of Genimen. He is a globally recognized expert in the field of nutrition research. Professor Duttaroy is currently Group Leader of Chronic Disease at the University of Oslo’s Faculty of Medicine, and he is the editor in chief of the international peer reviewed journal Food & Nutrition Research. His scientific work has been published in over 175 original contributions, reviews, book, and editorials. He owns several international patents. His discoveries of anti-thrombotic factors in tomatoes and kiwifruits are patented internationally and 2 companies, Provexis Limited (www.provexis.com) in UK, and IDIA AS (www.idia.no) in Norway are established to commercialize these discoveries.
  • 14. Growth Rate The Nutraceutical market in India is estimated to grow to $2731 Million in 2016 at a CAGR (compound annual growth rate) of 13% and the revenues expected to reach approximately USD 4.2 billion in 2017. Investments Genimen is currently seeking funding for the implementation of the development plan leading to an FSSAI approval of health claims and full market access. The development is expected to continue to be supported by public funding. Genimen is extensively trying to raise the fund that provides funding for its corporate activities through 2015.
  • 15. Achievements and Targets  Genimen Pharmacon has won over the KFE license from Inven2 outperforming other competitors  We are on negotiating phase with IDIA AS, a Norwegian company which is holding the KFE License on a global platform (India excluded) for manufacturing and supplying of KFE for some of IDIA’s territory  Genimen Pharmacon is trying to collaborate with IDIA on mutual sharing of clinical trial data, allowing us to get the first hand data ensuring data quality  Prof Asim Duttaroy is the member of the scientific advisory board of Genimen Pharmacon  We are in touch with FSSAI (food safety and standards authority of India) pertaining to the regulatory approval of Kiwidrin for its commercialization in India Genimen Pharmacon has been able to achieve the above milestone over a span of few months only and working relentlessly towards the achievement of its targets. Going forward we need to forth set our strategic plan in taking the KFE to the end consumers. We welcome rational investors in aiding us financially to take things ahead from here.
  • 16. FAQ’S 1) What is the issue / pain point that your product / solution addresses • Explain why your customers need your solution …... Genimen Pharmacon focuses on cardiovascular disease (CVD) as it is the number one cause of death throughout the world based on report from World Health Organization • Mention what they are currently doing and how your product/service is a better solution …. They are either on low dose Aspirin or other antihypertensive drug which are synthetically made and has got side effects. Better Solution because our product will be used for lowering down the risk of CVD and is a natural extract which has no side effect. Moreover Aspirin has been rejected by USFDA for its use as primary prevention of CVD because there are serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and brain, in situations where the benefit of aspirin for primary prevention has not been established.
  • 17. FAQ’S… 2) Business model • This is about how you will make money from this business opportunity. 1. According to WHO data CVD is the number one causative factor for death all over the world and India which holds 1/6th of world’s population is of no exception 2. We are the sole licensee in India 3. Plan is to go for contract manufacturing and distribution with Grade 1 Company having Nutraceutical manufacturing license. Preferably on a royalty basis or profit sharing percentage. 4. The revenue generation will be huge naturally 3) What is the size of the market opportunity? As per the census of 2010, the percentage age group between 15 to 59 age is 61.6 % (http://www.censusindia.gov.in/vital_statistics/srs/Chap_2_-_2010.pdf) We are assuming the target age group to be of 25 to 60 years. Based on conventional approach 77.77 % of population should be between 25 to 60 which will be our target group. Now 61.6 percent of Indian population comes around 74 crores approximately whose 77.77 percent roughly becomes 57 crores. Even if we consider 10 percent of the population (5.7 crores approx) buys our product which may have a profit of Re 1 per capsule, still we end up with a profit of around (5.7 * 30) 171 crores on monthly basis. All this is at the start up level.
  • 18. Products in the pipe line Genimen Pharmacon is also doing research and development for the following diseases which are growing at an alarming rate globally  Diabetes mellitus  Foetal health and development  Memory Disorders  Preeclampsia and pregnancy disorders